BRAIN Biotech

Annual Report 2022/23

Annual Report 2022/23

Company

Why invest in BRAIN Biotech?

Five reasons to invest in BRAIN Biotech AG:

Three white icons: DNA strand, plant and seed
Reason 1
By investing in BRAIN Biotech AG, you are investing in sustainable growth in the dawning age of biology
Reason 1

By investing in BRAIN Biotech AG, you are investing in sustainable growth in the dawning age of biology

Three white icons: DNA strand, plant and seed

Since the company was founded in 1993, BRAIN Biotech AG has developed from a sought-after specialist in biotechnological research and development into an integrated company that covers the entire value chain from laboratory through to production. With our disruptive bio-based products and solutions with a focus on nutrition, health, and the environment, we support the development of the economy towards a bioeconomy. We focus entirely on customers in the B2B segment.

Three white icons: Syringe, plant and steaming bowl
Reason 2
With our solutions, we address some of the megatopics for a better, healthier, and more sustainable life
Reason 2

With our solutions, we address some of the megatopics for a better, healthier, and more sustainable life

Three white icons: Syringe, plant and steaming bowl

Our own R&D as well as the research programs we conduct together with our partners aim to develop solutions that lead to a better, healthier, and more sustainable life. Non-disclosure agreements prevent us from presenting all R&D programs publicly, but some highlights include:

  • Natural-based sweeteners: The identification and development of new natural-based sweeteners and sweetness enhancers.
  • Gold recycling from waste streams: Computer scrap, slag, and other waste of mineral origin: Biological extraction processes replace conventional chemical processes.
  • Battery recycling: Biological processes for recycling precious metals and lithium, together with our industrial partners.
  • Enzymatic cleansing of chronic wounds (Aurase): Painful and risky methods can be avoided. SolasCure spin-out in 2018 to implement the pharmaceutical approval process.
  • Nature-based substances: For tastier and healthier non-alcoholic drinks on a natural basis.
  • Circular economy in which waste is turned into raw materials: Carbon dioxide as a raw material for chemicals.
  • Identify plant-based antimicrobial candidates for food preservation: Can also be used for other industrial applications.
  • Active ingredient for the treatment of hereditary angioedema (rare hereditary disease): PHA121 in clinical development by our cooperation partner Pharvaris.
Two white icons: Industrial building and cycle with arrows
Reason 3
We actively contribute to more sustainable industrial production and entry into the circular economy
Reason 3

We actively contribute to more sustainable industrial production and entry into the circular economy

Two white icons: Industrial building and cycle with arrows

BRAIN Biotech is a leading company in the service of the bioeconomy. In this type of economy, biotechnological processes are harnessed for sustainable production on a natural basis. Our focus is on industrial biotechnology (“white biotechnology”).

Among other projects, we are striving to replace petrochemical processes with biotechnological processes on the basis of our proprietary collection of resources, the BRAIN BioArchive.

We improve industrial processes and develop new products and services by not limiting ourselves to individual analytical or molecular biological technologies. Our products and solutions directly address the following United Nations Sustainable Development Goals (UN SDGs): 2, 3, 6, 9, 12 and 13. More information and specific examples are presented in in our ESG and Sustainability Report

A computer monitor with several statistics icons
Reason 4
We have an attractive portfolio of biotechnology solutions and processes
Reason 4

We have an attractive portfolio of biotechnology solutions and processes

A computer monitor with several statistics icons

We possess extensive and well-founded knowledge concerning enzymes, microorganisms, cell-based test systems, and bioactive natural compounds. An interdisciplinary approach enables us to conceive and develop completely new products and services for our customers.

We do not limit ourselves to individual technologies and methods, but instead leverage our broad technology portfolio.

Bioinformatics forms a central element of our R&D expertise for faster and better solutions. In addition to our employees’ experience, we rely here on state-of-the-art technologies in the machine learning and artificial intelligence areas.

The targeted modification and programming of cells is one of BRAIN Biotech’s core competencies. In this context, we deploy all commercially available technologies as well as our proprietary nucleases G-dase M® and G-dase E® for genome editing.

We are an expert solution provider for industry – from research and the scaling up of industrial biological processes to the production of enzymes and proteins.

More than thirty years of experience, around 600 available products for our B2B customers, and over 200 successfully completed industrial cooperation projects are strong testimony to our success.

A white euro sign with an ascending arrow diagram
Reason 5
We have embarked on a clear path towards profitable growth
Reason 5

We have embarked on a clear path towards profitable growth

A white euro sign with an ascending arrow diagram

We have been on a clear growth track again for the last two years. We aim to double the Group’s revenue in the medium term while at the same time increasing the adjusted EBITDA margin.

The BioProducts area is the Group’s primary growth segment. We have already invested heavily in expanding production capacity at our sites in recent years.

Our growth strategy is geographically focused on Europe and North America.

We offer highly innovative solutions and products for our customers through the close integration of our biotechnological research and production expertise.

Key figures

  • 55.3 Million

    Revenue, generated in FY 2022/23

  • 0.4 Million

    Adjusted EBITDA

  • 32 %

    Equity ratio

  • ~ 600

    Specialty products for B2B

  • 40

    Active patent families with varying numbers of individual patents

  • ~ 200

    Number of successfully completed R&D projects with industrial partners

Stories

Specialty enzymes for niche markets
How BRAIN Biotech Group`s technology units contribute to the development and market launch of developing specialty enzymes
Read more
High-performance production strains for enzymes and proteins
An Aspergillus niger strain developed by BRAIN Biotech has proven suitable to be an efficient production strain for enzymes and alternative proteins - with yields in the "double-digit" gram per liter range. Interdisciplinary teamwork was the basis for this success.
Read more
30 Years "Biotech the Future"
BRAIN Biotech celebrated its 30th anniversary at its Zwingenberg site under the motto "Biotech the Future". The focus was on meetings with business partners and long-time companions.
Read more
Akribion Genomics receives the Hessian Founder Award
The Akribion Genomics team of BRAIN Biotech AG has received the Hessian Founder Award for its innovative approach to a new cancer therapy
Read more
Akribion Genomics team successfully competes in Science4Life Venture Cup competition
BRAIN´s Akribion Genomics team has been awarded second place for its concept and business plan for their CRISPR-based cell killing tools for therapeutic applications
Read more